Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 5, 2014, Pages 389-394

  Ahn, Jae Sook ^a   Jung, Sung Hoon ^a   Yang, Deok Hwan ^a   Bae, Soo Young ^b   Kim, Yeo Kyeoung ^a   Kim, Hyeoung Joon ^a   Lee, Je Jung ^a  

^a Chonnam National University   (South Korea)

^b St Carollo Hospital   (South Korea)

Author keywords

Clonal evolution; Free light chain; Light chain escape; Plasma cell leukemia; Plasmacytomas

Indexed keywords

BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; M PROTEIN; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN LIGHT CHAIN; PARAPROTEIN; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BONE LESION; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; LIGHT CHAIN; LIGHT CHAIN ESCAPE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PLASMACYTOMA; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL CLONE; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; SOUTH KOREA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLONE CELLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; MYELOMA PROTEINS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PLASMACYTOMA; PROGNOSIS; PROTEASOME INHIBITORS; PYRAZINES; RECURRENCE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 84908666540     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.02.004     Document Type: Article

References (19)

1. X. Qu, L. Zhang, and W. Fu An infrequent relapse of multiple myeloma predominantly manifesting as light chain escape: clinical experience from two Chinese centers Leuk Lymphoma 51 2010 1844 1849
2. G.P. Mead, H.D. Carr-Smith, and M.T. Drayson Serum free light chains for monitoring multiple myeloma Br J Haematol 126 2004 348 354
3. A. Dispenzieri, R. Kyle, and G. Merlini International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders Leukemia 23 2009 215 224
4. J.A. Katzmann, R.J. Clark, and R.S. Abraham Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains Clin Chem 48 2002 1437 1444
5. S.K. Kumar, S.V. Rajkumar, and A. Dispenzieri Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2008 2516 2520
6. H.J. Park, E.H. Park, and K.W. Jung Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008 Korean J Hematol 47 2012 28 38
7. D. Zamarin, S. Giralt, and H. Landau Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation Bone Marrow Transplant 48 2013 419 424
8. A. Alegre, A. Granda, and C. Martinez-Chamorro Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry Haematologica 87 2002 609 614
9. S. Lenhoff, M. Hjorth, and I. Turesson Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation Haematologica 91 2006 1228 1233
10. N.J. Bahlis Darwinian evolution and tiding clones in multiple myeloma Blood 120 2012 927 928
11. A. Palumbo, I. Avonto, and B. Bruno Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma Eur J Haematol 76 2006 273 277
12. C. Kyriakou, K. Thomson, and S. D'Sa Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma Br J Haematol 129 2005 763 770
13. M.H. Kropff, N. Lang, and G. Bisping Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma Br J Haematol 122 2003 607 616
14. B.G. Durie, J.L. Harousseau, and J.S. Miguel International uniform response criteria for multiple myeloma Leukemia 20 2006 1467 1473
15. J.S. Ahn, D.H. Yang, and S.H. Jung A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma Ann Hematol 91 2012 1023 1030
16. Y.K. Kim, S.K. Sohn, and J.H. Lee Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study Ann Hematol 89 2010 475 482
17. J.B. Egan, C.X. Shi, and W. Tembe Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides Blood 120 2012 1060 1066
18. J.J. Keats, M. Chesi, and J.B. Egan Clonal competition with alternating dominance in multiple myeloma Blood 120 2012 1067 1076
19. M. Dimopoulos, R. Kyle, and J.P. Fermand Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 Blood 117 2011 4701 4705